

04-18-07

JPW \$

Express Mail Label No. EV 970 576 620 US

Attorney Docket No.: 41714-8016.US00



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: KOZLOWSKI ET AL.

APPLICATION No.: 10/751,274

FILED: December 31, 2003

FOR: HYDROLYTICALLY STABLE MALEIMIDE-TERMINATED POLYMERS

EXAMINER: RABAGO, ROBERTO

ART UNIT: 1713

CONF. NO: 7476

Information Disclosure Statement After First Office Action but Before Final Action or Notice of Allowance 37 CFR 1.97(c)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

04/18/2007 WASFAW1 00000052 502207 10751274
01 FC:1806 100.00 DA

Sir:

1. Timing of Submission

The information transmitted herewith is being filed *after* three months of the filing date of this application or after the mailing date of the first Office action on the merits, whichever occurred last, but *before* the mailing date of either a final action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. §1.311, whichever occurs first. The references listed on the enclosed Form PTO-1449 (modified) may be material to the examination of this application; the Examiner is requested to make them of record in the application.

2. Cited Information

☒ Copies of references 1-12 are enclosed.

3. Effect of Information Disclosure Statement (37 C.F.R. § 1.97(h))

This Information Disclosure Statement is not to be construed as a representation that: (i) a search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the cited information is, or is considered to be, material to patentability. In addition, applicant does not admit that any enclosed item of information constitutes prior art to the subject invention and specifically reserves the right to demonstrate that any such reference is not prior art.


4. Fee Payment (37 C.F.R. § 1.97(c)) or Certification (37 C.F.R. § 1.97(e))
☒ Applicant elects to pay the fee under 37 CFR 1.17(p) in the amount of \$180.00.
☒ Please charge Deposit Account No. 50-2207 in the amount of \$180.00.
☒ The Commissioner is hereby authorized to charge any deficiency in fees to ensure timely submission of these papers to Deposit Account No. 50-2207.

5. Patent Term Adjustment (37 C.F.R. § 1.704(d))

- ☐ The undersigned states that each item of information submitted herewith was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this statement. 37 C.F.R. § 1.704(d).

Respectfully submitted,
Perkins Coie LLP

Date: April 17, 2007


Susan T. Evans


Registration No. 38,443
on behalf of Nektar Therapeutics

Correspondence Address:

Nektar Therapeutics
150 Industrial Road
San Carlos, CA 94070

Please type a plus sign (+) inside this box →

+



PTO/SB/08A (08-0)

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/751,274
				Filing Date	December 31, 2003
				Confirmation Number	7476
				First Named Inventor	Kozlowski <i>et al.</i>
				Group Art Unit	1713
				Examiner Name	Rabago, Roberto
Sheet	1	of	1	Attorney Docket Number	41714-8016.US00 (SHE0063.00)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	1.	Enzon Pharmaceuticals Catalog, "Macromolecular Engineering Technologies," pp: 1-14 (2004).	
	2.	Nektar Molecule Engineering Catalog, "Polyethylene Glycol and Derivatives for Advanced PEGylation," pp: 1-21 (2003).	
	3.	Nektar Advanced PEGylation Catalog, "Polyethylene Glycol and Derivatives for Advanced PEGylation," pp: 1-24 (2004).	
	4.	Nektar Advanced PEGylation Catalog, "Polyethylene Glycol and Derivatives for Advanced PEGylation," pp: 1-30 (2005-2006).	
	5.	NOF Corporation Catalog, "Peg Derivatives, Phospholipid and Drug Delivery Materials for Pharmaceuticals," 1: pp: 2-46 (2003).	
	6.	Polypure Products Catalog, April 2005.	
	7.	Quanta Biodesign Catalog, "Labeling, Modification and Crosslinking Reagents Incorporating our Unique Monodispersed dPEG™ Technology," pp: 1-38, March 12, 2004.	
	8.	Quanta Biodesign Catalog, "Labeling, Derivatization and Crosslinking Reagents for Biological and Related Materials with dPEG," pp: 1-31, November 5, 2004.	
	9.	Quanta Biodesign Product Catalog, "Leading Innovator, Producer and Provider of Monodisperse Discrete PEG (dPEG) Derivatives," pp: 1-51, November 17, 2005.	
	10.	Shearwater Polymers, Inc., Catalog, , "Functionalized Biocompatible Polymers for Research: Polyethylene Glycol and Derivatives," pp: 2-49 (March, 1995).	
	11.	Shearwater Polymers, Inc., Catalog, , "Functionalized Biocompatible Polymers for Research and Pharmaceuticals: Polyethylene Glycol and Derivatives," pp: 2-53 (1997-1998).	
	12.	Shearwater Polymers, Inc., Catalog, "Functionalized Biocompatible Polymers for Research and Pharmaceuticals: Polyethylene Glycol and Derivatives," pp: 2-50 (2000).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number.

¹ Applicant is to place a check mark here if English language Translation attached.